Enhancer of zeste homolog 2 (EZH2), a histone methyltransferase and a catalytic
component of PRC2, catalyzes tri-methylation of histone H3 at Lys 27 (H3K27me3) to …

Enhancer of zeste homolog 2 (EZH2) is the catalytic subunit of polycomb repressive
complex 2 (PRC2). Dysregulation of EZH2 causes alteration of gene expression and …

While long noncoding RNAs (lncRNAs) have been reported to play an important role in
human cancer types, they remain poorly understood in papillary thyroid carcinoma (PTC) …

A major hurdle in the study of rare tumors is a lack of existing preclinical models.
Neuroendocrine prostate cancer is an uncommon and aggressive histologic variant of …

Lung squamous cell carcinoma (LUSC) is associated with poor clinical prognosis and lacks
available targeted therapy. Novel molecules are urgently required for the diagnosis and …

Simple Summary Enhancer of zeste homolog 2 (EZH2) modifies the trimethylation of Lys-27
of histone 3, affecting downstream target genes' expression. It was reported that EZH2 is …

Neuroblastoma is one of the commonest extra-cranial pediatric tumors, and accounts for
over 15% of all childhood cancer mortality. Risk stratification for children with neuroblastoma …

Cholangiocarcinoma (CCA) represents a diverse group of epithelial cancers associated with
the biliary tract, and can best be stratified anatomically into intrahepatic (iCCA), perihilar …

Brain tumors are responsible for high mortality and morbidity worldwide. The brain tumor
treatment depends on identification of molecular pathways involved in progression and …

The PRC2 and PRC1 complexes are aberrantly expressed in human cancers and have
been linked to decreases in patient survival. MUC1-C is an oncoprotein that is also …